Tapentadol hydrochloride manufacturers

Filters

None products found

tapentadol hydrochloride

Tablets, prolonged release (PR) 50 mg, 100 mg, 150 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Bolivia , Chile , Colombia , Costa Rica , Dominican Republic , El Salvador , Guatemala , Honduras , Nicaragua , Panama , Paraguay , Peru , Ukraine , Uruguay , Venezuela
Comments
DCP successful, RMS NL
Manufacturer #422

A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

tapentadol hydrochloride

Tablets, film coated 25 mg, 50 mg, 75 mg, 100 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Bolivia , Chile , Colombia , Costa Rica , Dominican Republic , El Salvador , Guatemala , Honduras , Nicaragua , Panama , Paraguay , Peru , Ukraine , Uruguay , Venezuela
Comments
DCP successful, RMS NL
Manufacturer #422

A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

tapentadol hydrochloride

Tablets, buccal 50 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply
Manufacturer #21844

Established in 2007, this manufacturer is a distinguished CTD dossier owner and manufacturer, widely recognized for its global reach in healthcare solutions. As a GMP manufacturer, it adheres to stringent quality standards across its production lines, selling products in multiple countries. The commitment of this CTD dossier owner and manufacturer to GMP manufacturer standards underscores its role in advancing pharmaceuticals and diagnostics, cementing its status as a leading CTD dossier owner and manufacturer.

 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About tapentadol hydrochloride

Tapentadol hydrochloride manufacturers include the originator Grünenthal (Palexia, Nucynta outside the US), Collegium Pharmaceutical (Nucynta in the US) and generic producers, with the first US generics approved in January 2026. Tapentadol is a centrally acting opioid analgesic with a dual mechanism: mu-opioid receptor activation and noradrenaline reuptake inhibition. It is used for moderate to severe acute pain and, as extended-release tablets, for chronic pain including diabetic neuropathic pain. Pharmaceutical companies can source tapentadol tablets and API through out-licensing, supply or technology transfer.

Tapentadol hydrochloride key facts

Property

Tapentadol hydrochloride

INN

Tapentadol (as hydrochloride)

Molecular formula / weight

C14H23NO · HCl / 257.8 g/mol

ATC code

N02AX06

Drug class

Opioid analgesic; mu-opioid agonist and noradrenaline reuptake inhibitor

Brand names

Nucynta, Nucynta ER (US, Collegium); Palexia, Palexia SR (Grünenthal, EU and other markets)

Originator

Grünenthal (Germany), developed with Johnson & Johnson

Dosage forms and strengths

Immediate-release tablets 50, 75, 100 mg; extended-release tablets 50–250 mg; oral solution (some markets)

Indications

Moderate to severe acute pain; severe chronic pain; diabetic peripheral neuropathic pain (extended-release, US)

Control status

US Schedule II; controlled in the EU and most countries

First approval

US FDA, November 2008 (immediate release)

Extended-release approval

US FDA, 2011

US generic status

First generics of Nucynta tablets and oral solution approved January 2026

Tapentadol hydrochloride manufacturers and licensing history

Grünenthal discovered tapentadol and developed it with Johnson & Johnson. The FDA approved Nucynta immediate-release tablets in November 2008, and Nucynta ER in 2011. In Europe and other markets, Grünenthal sells it as Palexia. US rights moved to Depomed and later to Collegium Pharmaceutical.

The first US generics of Nucynta tablets and oral solution were approved in January 2026. Extended-release products have separate patent and formulation considerations, including abuse-deterrent features.

Tapentadol is a Schedule II opioid in the US and controlled in most countries. Buyers should confirm controlled-substance licences, quotas, GMP status, a DMF and abuse-deterrent formulation data before choosing a dossier partner.

Tapentadol hydrochloride dosage forms and dossier types

Tapentadol is supplied as immediate-release tablets, extended-release tablets and, in some markets, oral solution.

Form

Strengths

Typical dossier

Notes

Tapentadol immediate-release tablets

50, 75, 100 mg

US ANDA; EU CTD

US generics approved January 2026

Tapentadol extended-release tablets

50, 100, 150, 200, 250 mg

US ANDA; EU CTD

Check patents and abuse-deterrent requirements

Tapentadol oral solution

Per national MA

US ANDA; EU CTD

US generic approved January 2026

Tapentadol hydrochloride API

Bulk

DMF; CEP

Controlled substance; DEA or national licence

Target market

Dossier format

Key requirement

United States

ANDA (eCTD)

Schedule II; DEA registration and quota

European Union

EU CTD

Reference Palexia; narcotics licences

Other markets

CTD

Import and export permits for controlled substances

Tapentadol hydrochloride regulatory and patent status

Tapentadol was approved in the US in November 2008 and is widely approved in Europe and other markets. The first US generics of immediate-release tablets and oral solution were approved in January 2026. Extended-release forms may still be protected by formulation patents. As an opioid, tapentadol carries boxed warnings about addiction, abuse, respiratory depression and serotonin syndrome.

Tapentadol hydrochloride mechanism of action and therapeutic use

Tapentadol activates mu-opioid receptors and blocks noradrenaline reuptake in the spinal cord and brain. The noradrenaline effect adds pain relief, especially for nerve pain, and allows lower opioid activity than some other opioids. Tapentadol is used for moderate to severe acute pain and, in extended-release form, for severe chronic pain, including diabetic nerve pain.

Tapentadol hydrochloride licensing and sourcing

Tapentadol suppliers and licensing partners typically offer dossier out-licensing, finished-product supply or technology transfer. Buyers usually compare GMP status, controlled-substance licences, formulation type and territory availability. Current offers and supplier contacts are listed among the tapentadol hydrochloride manufacturers on Pipelinepharma.

Frequently asked questions about tapentadol hydrochloride

Who are the main tapentadol manufacturers? Grünenthal sells Palexia outside the US, and Collegium sells Nucynta in the US. Generic makers received US approvals in January 2026.

Is there a generic version of tapentadol? Yes. The first US generics of Nucynta tablets and oral solution were approved in January 2026.

What forms and strengths of tapentadol are available? Tapentadol is available as 50–100 mg immediate-release tablets, 50–250 mg extended-release tablets and oral solution in some markets.

Is tapentadol a controlled substance? Yes. Tapentadol is a Schedule II opioid in the US and controlled in most countries.

How is tapentadol different from tramadol? Both combine opioid and monoamine effects. Tapentadol acts directly without needing liver activation and has a stronger opioid effect.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.